Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort

References

• Jemal A, Siegel R, Xu J, . Cancer statistics, 2010.CA Cancer J Clin2010;60:277–300.
   Google Scholar
• Turner JJ, Morton LM, Linet MS, . InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90–e98.
   PubMed Web of Science ®Google Scholar
• Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology 2005;37:409–419.
   PubMed Web of Science ®Google Scholar
• Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005;11:411–423.
   PubMed Web of Science ®Google Scholar
• Ahmed SA, Talal N. Sex hormones and the immune system—Part 2. Animal data. Baillieres Clin Rheumatol 1990;4:13–31.
   PubMed Web of Science ®Google Scholar
• Li JJ. Perspectives in hormonal carcinogenesis: animal models to human disease. Prog Clin Biol Res 1996;394:447–454.
   PubMedGoogle Scholar
• Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011;96:255–264.
   PubMed Web of Science ®Google Scholar
• Norgaard M, Poulsen AH, Pedersen L, . Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study. Br J Cancer 2006;94:1339–1341.
   PubMed Web of Science ®Google Scholar
• Mildon KH, Ansell P, Roman E, . Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study. Cancer Causes Control 2010;21:2079–2083.
   PubMed Web of Science ®Google Scholar
• Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol 2008;168:278–288.
   PubMed Web of Science ®Google Scholar
• Altieri A, Gallus S, Franceschi S, . Hormone replacement therapy and risk of lymphomas and myelomas. Eur J Cancer Prev 2004;13:349–351.
   PubMed Web of Science ®Google Scholar
• Fernandez E, Gallus S, Bosetti C, . Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003;105:408–412.
   PubMed Web of Science ®Google Scholar
• Landgren O, Zhang Y, Zahm SH, . Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006;15:2342–2347.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Richesson DA, . Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer 2009;124:2737–2743.
   PubMed Web of Science ®Google Scholar
• Beiderbeck AB, Holly EA, Sturkenboom MC, . No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003;14:639–644.
   PubMed Web of Science ®Google Scholar
• Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin's lymphoma in women. J Clin Oncol 2001;19:1381–1387.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Holford TR, Leaderer B, . Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419–428.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Vachon CM, Habermann TM, . Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2002;11:1466–1471.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang SS, Sullivan-Halley J, . Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer 2011;129: 974–982.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Jacobs EJ, . The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:2490–2501.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
   Google Scholar
• Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
   Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101–129.
   Web of Science ®Google Scholar
• Folsom AR, Mink PJ, Sellers TA, . Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128–1132.
   PubMed Web of Science ®Google Scholar
• Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118(Suppl. 12B):64–73.
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Gaikwad NW, Yang L, Weisenburger DD, . Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 2009;14:502–512.
   PubMed Web of Science ®Google Scholar
• Chakravarti D, Zahid M, Backora M, . Ortho-quinones of benzene and estrogens induce hyperproliferation of human peripheral blood mononuclear cells. Leuk Lymphoma 2006;47:2635–2644.
   PubMed Web of Science ®Google Scholar
• Lu F, Zahid M, Saeed M, . Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF- 10F cells. The effects of2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol 2007;105:150–158.
   Google Scholar
• Yasui T, Uemura H, Tezuka M, . Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 2001;56:38–44.
   PubMed Web of Science ®Google Scholar
• Lang TJ. Estrogen as an immunomodulator. Clin Immunol 2004;113:224–230.
   PubMed Web of Science ®Google Scholar
• Kincade PW, Medina KL, Payne KJ, . Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000;175:128–137.
   PubMed Web of Science ®Google Scholar
• Forsberg JG. Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis. Arch Toxicol 1984;55:79–90.
   PubMed Web of Science ®Google Scholar